BackgroundPrevious studies have shown seasonal variation in asthma exacerbations, peaking over the winter months. A single-inhaler triple therapy containing extrafine formulations of inhaled corticosteroid (ICS) beclomethasone dipropionate (BDP), long-acting β2-agonist formoterol fumarate (FF), and muscarinic antagonist glycopyrronium (G) is development for asthma.ObjectiveWe sought to evaluate...
